Conference call to take place on Tuesday, August 15 at 8:30
a.m. Eastern Time
HENDERSON, Nev, Aug. 9, 2023
/PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX)
("Volition") today announced it will host a conference call on
Tuesday, August 15 at 8.30 a.m. Eastern Time to discuss its financial
and operating results for the second quarter 2023, in addition to
providing a business update. Details of this event can also be
found below.
Event: VolitionRx Limited Second Quarter 2023
Earnings and Business Update Conference
Call
Date: Tuesday, August 15, 2023
Time: 8:30
a.m. U.S. Eastern Time
U.S. & Canada Dial-in:1-877-407-9716 (toll free)
U.K. Dial-in: 0 800 756 3429 (toll free)
Toll/International: 1-201-493-6779
Conference ID: 13740530
Cameron Reynolds, President and
Group Chief Executive Officer of Volition, will host the call along
with Terig Hughes, Group Chief Financial Officer, Dr. Tom Butera, Chief Executive Officer of Volition
Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor
Relations. The call will provide an update on important events
which have taken place in the second quarter of 2023 and upcoming
milestones.
A live audio webcast of the conference call will also be
available on the investor relations page of Volition's corporate
website at http://ir.volition.com. In addition, a telephone replay
of the call will be available until August
29, 2023. The replay dial-in numbers are 1-844-512-2921
(toll-free) in the U.S. and Canada
and 1-412-317-6671 (toll) internationally. Please use replay pin
number 13740530 .
About Volition
Volition is a multi-national epigenetics company powered by
Nu.Q®, its proprietary nucleosome quantification platform. Through
its subsidiaries, Volition is developing simple, easy to use, cost
effective blood tests to help diagnose and monitor a range of
life-altering diseases including some cancers and diseases
associated with NETosis such as sepsis and COVID-19. Early
diagnosis and monitoring have the potential to not only prolong the
life of patients but also improve their quality of life. The tests
are based on the science of Nucleosomics™, which is the practice of
identifying and measuring nucleosomes in the bloodstream or other
bodily fluid - an indication that disease is present.
Volition's research and development activities are centered in
Belgium, with an innovation
laboratory and office in the U.S. and additional offices in
London and Singapore.
The contents found at Volition's website address are not
incorporated by reference into this document and should not be
considered part of this document. Such website address is
included in this document as an inactive textual reference
only.
Nu.Q® is a trademark of VolitionRx Limited and its
subsidiaries.
Media Enquiries:
Louise Batchelor/Debra Daglish
Volition
mediarelations@volition.com
+44 (0)7557 774620
View original
content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-second-quarter-2023-earnings-conference-call-and-business-update-301896744.html
SOURCE VolitionRx Limited